Regulator of G Protein Signaling 4 Inhibits Human Melanoma Cells Proliferation and Invasion Through the PI3K/AKT Signaling Pathway

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 8

PMID 29108247

Citations 10

Authors

Xiaotong Xue

Lihua Wang

Xianguang Meng

Jing Jiao

Ningning Dang

Affiliations

Soon will be listed here.

Abstract

Melanoma is a tumor produced by skin melanocytes, which has a high metastatic rate and poor prognosis. So far, plenty of work has been done on melanoma, but mechanisms underlying melanoma development have not been fully elucidated. Here we identified regulator of G protein signaling 4(RGS4) as novel therapeutic target for malignant melanoma and its regulating effect on melanoma. We found that endogenous RGS4 expression was much lower in melanoma tissues and cells. In A375 cell line with low endogenous RGS4 expression, the function of RGS4 was detected by up-regulation its expression with pcDNA3.1-RGS4 and knockdown its expression with siRNA. Our results showed that RGS4 could significantly reduce the proliferation, migration and invasion of melanoma cells. RGS4 is an important regulator for the apoptosis of melanocyte, and the apoptosis rate is significantly decreased in low RGS4 enviroment. RGS4 induced non-activation of PI3K/AKT pathway, resulting in decreased expression of E2F1 and Cyclin D1, thus constraining cell proliferation and invasion. These results were further confirmed in M14 cell lines. Collectively, our findings show that RGS4 plays an important role in multiple cellular functions of melanoma development and is valuable to be a therapeutic target.

Citing Articles

RGS proteins and their roles in cancer: friend or foe?.

Li L, Xu Q, Tang C Cancer Cell Int. 2023; 23(1):81.

PMID: 37118788 PMC: 10148553. DOI: 10.1186/s12935-023-02932-8.

Polyphenon E Effects on Gene Expression in PC-3 Prostate Cancer Cells.

Carastro L, Vallebuona E, Cordova R, Gannon A, Kim S, Costello C Int J Mol Sci. 2022; 23(22).

PMID: 36430806 PMC: 9697490. DOI: 10.3390/ijms232214328.

Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling Predicted by Three-Dimensional Missense Tolerance Ratio Analysis.

Montanez-Miranda C, Perszyk R, Harbin N, Okalova J, Ramineni S, Traynelis S Mol Pharmacol. 2022; 103(1):21-37.

PMID: 36384958 PMC: 10955721. DOI: 10.1124/molpharm.122.000614.

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors.

Cao L, Zheng K, Liu Y, Song P, Wang C, Wang H Front Genet. 2022; 13:878145.

PMID: 35646090 PMC: 9136294. DOI: 10.3389/fgene.2022.878145.

Oxidative Stress in Intestinal Ischemia-Reperfusion.

Li G, Wang S, Fan Z Front Med (Lausanne). 2022; 8:750731.

PMID: 35096858 PMC: 8795364. DOI: 10.3389/fmed.2021.750731.

References

Huang X, Charbeneau R, Fu Y, Kaur K, Gerin I, MacDougald O . Resistance to diet-induced obesity and improved insulin sensitivity in mice with a regulator of G protein signaling-insensitive G184S Gnai2 allele. Diabetes. 2007; 57(1):77-85. DOI: 10.2337/db07-0599. View

Tyndall J, Sandilya R . GPCR agonists and antagonists in the clinic. Med Chem. 2006; 1(4):405-21. DOI: 10.2174/1573406054368675. View

Bartolome R, Ferreiro S, Miquilena-Colina M, Martinez-Prats L, Soto-Montenegro M, Garcia-Bernal D . The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol. 2009; 174(2):602-12. PMC: 2630568. DOI: 10.2353/ajpath.2009.080636. View

Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K . The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005; 10:2986-3001. DOI: 10.2741/1755. View

King N, Hittinger C, Carroll S . Evolution of key cell signaling and adhesion protein families predates animal origins. Science. 2003; 301(5631):361-3. DOI: 10.1126/science.1083853. View

Cheng C, Yue W, Li L, Li S, Gao C, Si L . Regulator of G-protein signaling 4: A novel tumor suppressor with prognostic significance in non-small cell lung cancer. Biochem Biophys Res Commun. 2015; 469(3):384-91. DOI: 10.1016/j.bbrc.2015.11.110. View

Shin J, Song I, Pak J, Jang S . Upregulation of annexin A1 expression by butyrate in human melanoma cells induces invasion by inhibiting E-cadherin expression. Tumour Biol. 2016; 37(11):14577-14584. DOI: 10.1007/s13277-016-5306-5. View

Gajos-Michniewicz A, Czyz M . Modulation of WNT/β-catenin pathway in melanoma by biologically active components derived from plants. Fitoterapia. 2016; 109:283-92. DOI: 10.1016/j.fitote.2016.02.002. View

Overington J, Al-Lazikani B, Hopkins A . How many drug targets are there?. Nat Rev Drug Discov. 2006; 5(12):993-6. DOI: 10.1038/nrd2199. View

10.

Inamdar G, Madhunapantula S, Robertson G . Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010; 80(5):624-37. PMC: 2897908. DOI: 10.1016/j.bcp.2010.04.029. View

11.

Fu Y, Huang X, Zhong H, Mortensen R, DAlecy L, Neubig R . Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects. Circ Res. 2006; 98(5):659-66. DOI: 10.1161/01.RES.0000207497.50477.60. View

12.

Park P, Lodowski D, Palczewski K . Activation of G protein-coupled receptors: beyond two-state models and tertiary conformational changes. Annu Rev Pharmacol Toxicol. 2007; 48:107-41. PMC: 2639654. DOI: 10.1146/annurev.pharmtox.48.113006.094630. View

13.

Miller T, Rexer B, Garrett J, Arteaga C . Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011; 13(6):224. PMC: 3315683. DOI: 10.1186/bcr3039. View

14.

Chen X, Dong H, Liu S, Yu L, Yan D, Yao X . Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway. Am J Transl Res. 2017; 9(1):90-102. PMC: 5250706. View

15.

Xu Z, Zuo Y, Wang J, Yu Z, Peng F, Chen Y . Overexpression of the regulator of G-protein signaling 5 reduces the survival rate and enhances the radiation response of human lung cancer cells. Oncol Rep. 2015; 33(6):2899-907. DOI: 10.3892/or.2015.3917. View

16.

Lee S, Um S, Kim E . CBX8 antagonizes the effect of Sirtinol on premature senescence through the AKT-RB-E2F1 pathway in K562 leukemia cells. Biochem Biophys Res Commun. 2016; 469(4):884-90. DOI: 10.1016/j.bbrc.2015.12.070. View

17.

Ross E, Wilkie T . GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem. 2000; 69:795-827. DOI: 10.1146/annurev.biochem.69.1.795. View

18.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

19.

Naqsh e Zahra S, Khattak N, Mir A . Comparative modeling and docking studies of p16ink4/cyclin D1/Rb pathway genes in lung cancer revealed functionally interactive residue of RB1 and its functional partner E2F1. Theor Biol Med Model. 2013; 10:1. PMC: 3563505. DOI: 10.1186/1742-4682-10-1. View

20.

Wang Z, Huang H, He W, Kong B, Hu H, Fan Y . Regulator of G-protein signaling 5 protects cardiomyocytes against apoptosis during in vitro cardiac ischemia-reperfusion in mice by inhibiting both JNK1/2 and P38 signaling pathways. Biochem Biophys Res Commun. 2016; 473(2):551-7. DOI: 10.1016/j.bbrc.2016.03.114. View